or
forgot password

A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Advanced Squamous Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer


Inclusion Criteria:



- Histologically or cytologically confirmed advanced squamous NSCLC

- Measurable disease as defined per modified RECIST criteria

- ECOG performance status of 0 or 1

- ≥18 years old

- Adequate glycemic function, for subjects with known diabetes

Exclusion Criteria:

- Untreated or symptomatic central nervous system (CNS) metastases

- Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any
prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior
chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior
to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment
for squamous NSCLC

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities

Outcome Time Frame:

Part 1 Only

Safety Issue:

Yes

Principal Investigator

MD

Investigator Role:

Study Director

Investigator Affiliation:

Amgen

Authority:

United States: Food and Drug Administration

Study ID:

20080257

NCT ID:

NCT00807612

Start Date:

January 2009

Completion Date:

August 2010

Related Keywords:

  • Advanced Squamous Non-Small Cell Lung Cancer
  • AMG 479
  • IGF-1R
  • Apoptosis
  • Monoclonal Antibody
  • Advanced Squamous Non-Small Cell Lung Cancer
  • antibody 1st-line
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Research Site Bentonville, Arkansas  
Research Site Bloomington, Indiana  
Research Site Ashland, Kentucky  
Research Site Branson, Missouri  
Research Site Asheville, North Carolina  
Research Site Allentown, Pennsylvania  
Research Site Charleston, South Carolina  
Research Site Chattanooga, Tennessee  
Research Site Appleton, Wisconsin